Small Cell Lung Cancer (SCLC) is malignant form of cancer arising within the lungs. SCLC is characterized by high growth rate, shorter doubling time than the non-small cell lung tumors. SCLC is more responsive to chemotherapy than NSCLC. Small cell lung cancer is highly associated with tobacco, unhealthy food, alcohol, HIV infected, chronic infections or related family history, and physical inactivity. The decrease in smoking is reflected as the substantial decrease in the incidence of SCLC. The symptoms include dyspnea, blood in sputum, weight loss, cough, and debility.
Request Sample PDF of the Report @ https://www.coherentmarketinsights.com/insight/request-sample/799
Global rise in number of cancer cases expected to support the growth of small cell lung cancer therapeutics market in the near future
According to the American Cancer Society Statistics in 2016, maximum cases of SCLC occur in individuals aged 60-80 years with an estimated global death rate being 30,000 per year. Also, according to the World Health Organization (WHO), lung cancer is the second most prevailing cancer in men and women causing 1.59 million deaths in 2012. The rising prevalence of lung cancer, rise in unhealthy lifestyle, the launch of innovative radiation therapies, and premium priced drugs are the major factors driving the growth of lung cancer therapeutics market. Additionally, rising demand for targeted therapies and platinum-based chemotherapies is likely to have an optimistic impact on the small lung cancer therapeutics market in the forecast period. Also, increasing diagnostic facilities by the government, provision of guidelines to cancer patients by International Healthcare Organizations are the major factors contributing to the rising of small cell lung cancer market. However, expensive treatments, lack of awareness leading to late diagnosis are the major factors restraining the small cell lung cancer market growth.
Ask for a Discount @ https://www.coherentmarketinsights.com/insight/request-discount/799
Platinum derivatives segment accounts for highest revenue share owing to the higher metastasis control rate
The global small cell lung cancer therapeutics market is segmented on the basis of drug therapy, and distribution channel.
On the basis of drug therapy, the global small cell lung cancer therapeutics market is segmented into:
- Targeted Therapy Drugs
- Immunotherapy Drugs
- Platinum Derivatives
On the basis of distribution channel, the global small cell lung cancer therapeutics market is segmented into:
- Hospital Pharmacies
- Retail and Online Pharmacies
Enhanced health care dynamics to boost the Asia Pacific small cell lung cancer market
Regional segmentation of small cell lung cancer therapeutics market by Coherent Market Insights comprises of North America, Europe, Asia Pacific, Latin America, the Middle East and Africa. According to the American Cancer Society Statistics in 2017, around 222,500 cases of lung cancer were diagnosed with 116,990 prevailing in men and 105,510 in women, where small cell lung cancer accounts for 15 percent of lung cancers in the U.S. North America is expected to dominate the market owing to the high developed regions, improved healthcare setup, and growing awareness about healthcare. Asia Pacific is expected to drive the growth of SCLC market in the forecast period owing to the growing awareness of health care, government funding, and the presence of medical requirements for cancer therapeutics in the emerging economies such as India and China.
Read the article on the website @ https://www.coherentmarketinsights.com/ongoing-insight/small-cell-lung-cancer-therapeutics-market-799
Key players in the Small Cell Lung Cancer Therapeutics Market
Key players operating the small cell lung cancer therapeutics market include Bristol-Myers Squibb, GlaxoSmithKline, Menarini, Sanofi, and ZIOPHARM Oncology.